tbuckley/cabot-search huggingface dataset:
Financialisation: a 21st century commercial determinant of health equity
Authors: Sharon Friel, Ashley Schram, Nick Frank, Megan Arthur, Bel Townsend, Hridesh Gajurel
Journal: The Lancet Public Health (2024)

In 21st century capitalism, financial markets reign supreme. The elevation of investing, trading, and speculating as a way of making profit has shifted economic power towards institutional investors and enhanced the power of financial capital. Financialisation has introduced uncertainty in the commitment to public provision of goods and services. The behaviours of corporations focus more on profit for shareholders and senior executives to the detriment of wages, worker protections, livelihoods, and impact on prices and the environment. The practices of this financial system pose major challenges to public health and planetary health equity through the influence on social inequality, climate change, and health outcomes. The aim of this Viewpoint is to expand the understanding of the commercial determinants of health to explicitly include the financial system and present key plausible pathways via which the financialisation of advanced economies influences public health and planetary health equity. The global public health community must pay close attention to these key commercial determinants of health. It is now crucial to reduce the power of financial actors and hold financial actors accountable. Civil society groups can highlight their practices, articulate alternative visions, and hold financial actors and governments to account. Interdisciplinary research must provide a diagnosis of the financial and public health issues, and, importantly, illuminate effective pathways forward. Financial and commercial worlds must return to stakeholder primacy rather than that of the shareholder.
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study
Authors: Gabrielle Virgili-Gervais, Bianca Matthews, Elsa-Lynn Nassar, Marie-Eve Carrier, Linda Kwakkenbos, John D Pauling, Susan J Bartlett, Amy Gietzen, Karen Gottesman, Geneviève Guillot, Marie Hudson, Laura K Hummers, Amanda Lawrie-Jones, Vanessa L Malcarne, Maureen D Mayes, Michelle Richard, Maureen Sauvé, Robyn K Wojeck, Luc Mouthon, Andrea Benedetti, Brett D Thombs
Journal: The Lancet Rheumatology (2024)
Time trends in the epidemiology of food allergy in England: an observational analysis of Clinical Practice Research Datalink data
Authors: Paul J Turner, Alessia Baseggio Conrado, Constantinos Kallis, Eimear O'Rourke, Sadia Haider, Anhar Ullah, Darije Custovic, Adnan Custovic, Jennifer K Quint
Journal: The Lancet Public Health (2024)

Estimates for the prevalence of food allergy vary widely, with a paucity of data for adults. The aim of this analysis was to report trends in the incidence and prevalence of food allergy in England, using a national primary care dataset.
Endoscopic ultrasound‐guided versus percutaneous liver biopsy: a systematic review and meta-analysis of randomized controlled trials
Authors: Paula Arruda do Espirito Santo, Gilmara Coelho Meine, Angélica Luciana Nau, Eduardo Cerchi Barbosa, Stefano Baraldo, Luciano Lenz, Fauze Maluf-Filho
Journal: Endoscopy (2024)

Abstract Background Percutaneous liver biopsy (PC-LB) has long been the usual method for acquisition of liver tissue. Recently, endoscopic ultrasound-guided liver biopsy (EUS-LB) has gained popularity as an alternative modality. We aimed to compare the efficacy and safety of EUS-LB versus PC-LB. Methods We systematically searched PubMed, Embase, and the Cochrane Library databases for randomized controlled trials (RCTs) comparing EUS-LB with PC-LB published until October 20, 2023. The primary outcome was diagnostic adequacy. Secondary outcomes were: the number of complete portal tracts (CPTs), longest sample length (LSL), total sample length (TSL), post-procedure pain scores, and adverse events (AEs), including overall AEs and AEs excluding minor post-procedure symptoms. We compared binary outcomes using risk ratios (RRs) and continuous outcomes using the mean difference (MD) or standardized mean difference (SMD), with 95%CIs. Results Four RCTs (258 patients) were included. The EUS-LB group presented lower post-procedure pain scores (SMD −0.58, 95%CI −0.95 to −0.22) than the PC-LB group. Both groups performed similarly in terms of diagnostic adequacy (RR 1.0, 95%CI 0.96 to 1.04), number of CPTs (MD 2.57, 95%CI −4.09 to 9.22), LSL (MD −2.91 mm, 95%CI −5.86 to 0.03), TSL (MD 4.16 mm, 95%CI −10.12 to 18.45), overall AEs (RR 0.54, 95%CI 0.20 to 1.46), and AEs excluding minor post-procedure symptoms (RR 1.65, 95%CI 0.21 to 13.02). Conclusions This meta-analysis suggests that EUS-LB is as safe and effective as PC-LB and is associated with lower post-procedure pain scores. Registration on PROSPERO: CRD42023469469.
Suspension electrospinning of decellularized extracellular matrix: A new method to preserve bioactivity
Authors: Sarah Jones, Sabrina VandenHeuvel, Andres Luengo Martinez, Ruchi Birur, Eric Burgeson, Isabelle Gilbert, Aaron Baker, Matthew Wolf, Shreya A Raghavan, Simon Rogers, Elizabeth Cosgriff-Hernandez
Journal: Bioactive Materials (2024)

Decellularized extracellular matrices (dECM) have strong regenerative potential as tissue engineering scaffolds; however, current clinical options for dECM scaffolds are limited to freeze-drying its native form into sheets. Electrospinning is a versatile scaffold fabrication technique that allows control of macro- and microarchitecture. It remains challenging to electrospin dECM, which has led researchers to either blend it with synthetic materials or use enzymatic digestion to fully solubilize the dECM. Both strategies reduce the innate bioactivity of dECM and limit its regenerative potential. Herein, we developed a new suspension electrospinning method to fabricate a pure dECM fibrous mesh that retains its innate bioactivity. Systematic investigation of suspension parameters was used to identify critical rheological properties required to instill "spinnability," including homogenization, concentration, and particle size. Homogenization enhanced particle interaction to impart the requisite elastic behavior to withstand electrostatic drawing without breaking. A direct correlation between concentration and viscosity was observed that altered fiber morphology; whereas, particle size had minimal impact on suspension properties and fiber morphology. The versatility of this new method was demonstrated by electrospinning dECM with three common decellularization techniques (Abraham, Badylak, Luo) and tissue sources (intestinal submucosa, heart, skin). Bioactivity retention after electrospinning was confirmed using cell proliferation, angiogenesis, and macrophage polarization assays. Collectively, these findings provide a framework for researchers to electrospin dECM for diverse tissue engineering applications.
Particle therapy for intrahepatic cholangiocarcinoma: A multicenter prospective registry study, systematic review and meta-analysis
Authors: Masashi Mizumoto, Kei Shibuya, Kazuki Terashima, Masao Murakami, Motohiro Murakami, Yoshiyuki Shioyama, Yoshiro Matsuo, Takashi Ogino, Tatsuya Ohno, Takahiro Waki, Hiroyuki Ogino, Hiroyasu Tamamura, Norio Katoh, Masaru Wakatsuki, Tomoaki Okimoto, Motohisa Suzuki, Takashi Saito, Shingo Toyama, Takayuki Hashimoto, Hisateru Ohba, Shoji Kubo, Kiyoshi Hasegawa, Kazushi Maruo, Hideyuki Sakurai
Journal: Liver Cancer (2024)

A prospective study was started in May 2016 to evaluate the efficacy and safety of particle therapy for intrahepatic cholangial carcinoma (ICC). To compare treatment modalities, we also conducted a meta-analysis of literature data and a systematic comparison using registry data. Patients who received particle therapy for ICC from May 2016 to June 2018 were registered. Nineteen manuscripts (4 particle therapy, 8 3D-CRT, 7 SBRT) were selected for the meta-analysis. A total of 85 cases (proton beam therapy 59, carbon therapy 26) were registered. The median overall survival (OS) of the 85 patients was 22.1 months (95% CI: 12.9-31.3); the 1-, 2-, 3-, and 4-year OS rates were 70.9% (95% CI: 61.1-80.7%), 47.6% (36.8-58.4%), 37.7% (26.7-48.7%), and 22.7% (10.2-35.2%), respectively; and the 1-, 2-, 3-, and 4-year local recurrence rates were 8.2% (1.1-15.3%), 21.6% (9.3-33.9%), 33.4% (16.7-50.1%), and 33.4% (16.7-50.1%), respectively. In the meta-analysis and registry data, the 1-year OS for particle therapy, SBRT and 3D-CRT were 71.8% (95% CI: 64.6-77.8%), 59.2% (53.0-64.9%, p = 0.0573), and 47.2% (36.8-56.9%, p = 0.0004), respectively. The incidence of grade 3 or higher late non-hematological toxicity in the meta-analysis and registry data were 7.4-12% for particle therapy, 6.7-16.7% for SBRT, and 8.1-14.3% for 3D-CRT. Particle therapy achieved a good therapeutic effect for ICC, and a meta-analysis indicated that particle therapy is a better treatment modality than SBRT and 3D-CRT.
Mpox in Pregnancy — Risks, Vertical Transmission, Prevention, and Treatment
Authors: Jean B Nachega, Emma L Mohr, Pradip Dashraath, Placide Mbala-Kingebeni, Jean R Anderson, Landon Myer, Monica Gandhi, David Baud, Lynne M Mofenson, Jean-Jacques Muyembe-Tamfum
Journal: New England Journal of Medicine (2024)
Insulin receptors in vascular smooth muscle cells regulate plaque stability of atherosclerosis
Authors: Qian Li, Jialin Fu, Kyoungmin Park, Hetal Shah, Qin Li, I Hsien Wu, George L King
Journal: Cardiovascular Research (2024)

Abstract Aims Increased prevalence of acute myocardial infarction related to diabetes and insulin resistance is associated with an elevated risk of unstable atherosclerotic plaques, which are characterized by reduced vascular smooth muscle cells (VSMCs) and extracellular matrix (ECM) and increased inflammation. Thus, insulin resistance may reduce plaque stability, as deleting insulin receptors (IRs) in VSMCs decreases their proliferation and enhances apoptosis. Methods and results Direct effects of insulin on VSMCs to alter plaque composition were studied using mice with double knockout of ApoE and IR genes in VSMCs with SMIRKO/ApoE−/−, Myh11-CreERT2EYFP+/ApoE−/−, and Myh11-CreERT2EYFP+IRKO/ApoE−/− mice, which were also used for lineage tracing studies. Compared with ApoE−/− mice, SMIRKO/ApoE−/− mice exhibited more atherosclerotic plaques, which contained less VSMCs and collagen but increased levels of VSMC apoptosis and necrotic areas. Lineage tracing studies showed that Icam1+ Vcam1+ VSMC was inflammatory, which increased in the aortas of Myh11-CreERT2EYFP+IRKO/ApoE−/− mice compared with control mice. Isolated VSMCs lacking IRs expressed higher inflammatory cytokines than cells with IRs. Cell-based studies indicated that insulin’s anti-apoptotic and pro-proliferative effects in VSMCs were mediated via activation of the IR/Akt pathway, which were decreased in VSMCs from SMIRKO or high-fat diet mice. An analysis of the IR targets that regulated inflammatory cytokines in VSMCs showed that thrombospondin 1 (Thbs1) and Mmp2 were consistently increased with a loss of IRs. Insulin inhibited Thbs1 expression, but not Mmp2 expression, through p-Akt/p-FoxO1 pathways in VSMCs from ApoE−/− mice, and was impaired in cells from SMIRKO/ApoE−/− mice. Thbs1 further induced Icam1 and Mmp2 expressions in VSMCs. Conclusion Insulin via IRs has significant actions in VSMCs to decrease inflammation, apoptosis, and ECM turnover via the activation of Akt and FoxO1 pathways. The inhibition of insulin actions and related pathways related to insulin resistance and diabetes may contribute to the formation of unstable atherosclerotic plaques.
Unlocking unknown mutations to understand causal relationships in cardiovascular science: paving the path to personalized cardiovascular care
Authors: Soumaya Ben-Aicha, Dorian Haskard
Journal: Cardiovascular Research (2024)

Multiple disorders are characterised by dysregulated inflammation, many of which entail genetic background.Genome-wide sequencing has provided the means to define the molecular basis of examples that may be rare or even unique.Importantly, such genetically determined autoinflammatory disorders provide proof-of-principle of molecular pathways in humans and may point the way to treating more common inflammatory conditions.Recent research has shed light on a previously unrecognized autoinflammatory condition arising from a mutation in the interleukin -1 receptor 1 (IL-1R1) gene, termed "Loss of IL-1R1 Sensitivity to IL-1Ra" (LIRSA).This novel discovery, highlighted in the study by Yusha Wang et al. published in Immunity 1 , offers crucial insights into the pathophysiology of autoinflammatory conditions and unveils promising avenues for targeted therapy.
Early coronary revascularization among “stable” patients with non-ST-segment elevation acute coronary syndromes: the role of diabetes and age
Authors: Natalia Fabin, Edina Cenko, Maria Bergami, Jinsung Yoon, Giuseppe Vadalà, Guiomar Mendieta, Sasko Kedev, Jorgo Kostov, Marija Vavlukis, Elif Vraynko, Davor Miličić, Zorana Vasiljevic, Marija Zdravkovic, Lina Badimon, Alfredo R Galassi, Olivia Manfrini, Raffaele Bugiardini
Journal: Cardiovascular Research (2024)

Abstract Aims To investigate the impact of an early coronary revascularization (&amp;lt;24 h) compared with initial conservative strategy on clinical outcomes in diabetic patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) who are in stable condition at hospital admission. Methods and results The International Survey of Acute Coronary Syndromes database was queried for a sample of diabetic and nondiabetic patients with diagnosis of NSTE-ACS. Patients with cardiac arrest, haemodynamic instability, and serious ventricular arrhythmias were excluded. The characteristics between groups were adjusted using logistic regression and inverse probability of treatment weighting models. Primary outcome measure was all-cause 30-day mortality. Risk ratios (RRs) and odds ratios (ORs) with their 95% confidence intervals (CIs) were employed. Of the 7589 NSTE-ACS patients identified, 2343 were diabetics. The data show a notable reduction in mortality for the elderly (&amp;gt;65 years) undergoing early revascularization compared to those receiving an initial conservative strategy both in the diabetic (3.3% vs. 6.7%; RR: 0.48; 95% CI: 0.28–0.80) and nondiabetic patients (2.7% vs. 4.7%: RR: 0.57; 95% CI: 0.36–0.90). In multivariate analyses, diabetes was a strong independent predictor of mortality in the elderly (OR: 1.43; 95% CI: 1.03–1.99), but not in the younger patients (OR: 1.04; 95% CI: 0.53–2.06). Conclusion Early coronary revascularization does not lead to any survival advantage within 30 days from admission in young NSTE-ACS patients who present to hospital in stable conditions with and without diabetes. An early invasive management strategy may be best reserved for the elderly. Factors beyond revascularization are of considerable importance for outcome in elderly diabetic subjects with NSTE-ACS. Clinical trial number ClinicalTrials.gov: NCT01218776.
Single-cell RNA-seq Reveals that Methamphetamine Inhibits Liver Immunity with Involvement of Dopamine Receptor D1
Authors: Jin-Ting Zhou, Yungang Xu, Xiao-Huan Liu, Cheng Cheng, Jing-Na Fan, Xiaoming Li, Jun Yu, Shengbin Li
Journal: Genomics Proteomics & Bioinformatics (2024)

Abstract Methamphetamine (METH) is a highly addictive psychostimulant that causes physical and psychological damage and immune system disorder, especially in the liver which contains a significant number of immune cells. Dopamine, a key neurotransmitter in METH addiction and immune regulation, plays a crucial role in this process. Here, we developed a chronic METH administration model and conducted single-cell RNA sequencing (scRNA-seq) to investigate the effect of METH on liver immune cells and the involvement of dopamine receptor D1 (DRD1). Our findings reveal that chronic exposure to METH induces immune cell identity shifts from IFITM3+ macrophage (Mac) and CCL5+ Mac to CD14+ Mac, as well as from FYN+CD4+ T effector (Teff), CD8+ T, and natural killer T (NKT) to FOS+CD4+ T and RORα+ group 2 innate lymphoid cell (ILC2), along with the suppression of multiple functional immune pathways. DRD1 is implicated in regulating certain pathways and identity shifts among the hepatic immune cells. Our results provide valuable insights into the development of targeted therapies to mitigate METH-induced immune impairment.
Bioresponsive and transformable coacervate actuated by intestinal peristalsis for targeted treatment of intestinal bleeding and inflammation
Authors: Yuqi Peng, Xiaofen Luo, Xinyu Wang, Enling Hu, Ruiqi Xie, Fei Lu, Weiwei Ding, Fangyin Dai, Guangqian Lan, Bitao Lu
Journal: Bioactive Materials (2024)
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
Authors: Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas, Akihiko Soyama, Chang-Tsu Yuan, Tse-Ching Chen, Susumu Eguchi, Tomoharu Yoshizumi, Shinji Itoh, Noriaki Nakamura, Hisashi Kosaka, Masaki Kaibori, Takamichi Ishii, Etsuro Hatano, Chikara Ogawa, Atsushi Naganuma, Satoru Kakizaki, Chih-Hsien Cheng, Po-Ting Lin, Yung-Yeh Su, Chien-Huai Chuang, Li-Chun Lu, Chi-Jung Wu, Hung-Wei Wang, Kun-Ming Rau, Chih-Hung Hsu, Shi-Ming Lin, Yi-Hsiang Huang, Sairy Hernandez, Richard S. Finn, Masatoshi Kudo, Ann-Lii Cheng
Journal: Journal of Clinical Oncology (2024)

PURPOSE Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of these patients and the histopathology of the residual tumors. PATIENTS AND METHODS The IMbrave150 study's atezo-bev group was analyzed. PR or SD per RECIST v1.1 lasting more than 6 months was defined as durable. For histologic analysis, a comparable real-world group of patients from Japan and Taiwan who had undergone resection of residual tumors after atezo-bev was investigated. RESULTS In the IMbrave150 study, 56 (77.8%) of the 72 PRs and 41 (28.5%) of the 144 SDs were considered durable. The median overall survival was not estimable for patients with durable PR and 23.7 months for those with durable SD. The median progression-free survival was 23.2 months for patients with durable PR and 13.2 months for those with durable SD. In the real-world setting, a total of 38 tumors were resected from 32 patients (23 PRs and nine SDs) receiving atezo-bev. Pathologic complete responses (PCRs) were more frequent in PR tumors than SD tumors (57.7% v 16.7%, P = .034). PCR rate correlated with time from atezo-bev initiation to resection and was 55.6% (5 of 9) for PR tumors resected beyond 8 months after starting atezo-bev, a time practically corresponding to the durable PR definition used for IMbrave150. We found no reliable radiologic features to predict PCR of the residual tumors. CONCLUSION Durable PR patients from the atezo-bev group showed a favorable outcome, which may be partly explained by the high rate of PCR lesions. Early recognition of PCR lesions may help subsequent treatment decision.
Genomic analysis of adult thrombotic microangiopathies in less than 3 days: From rapid to fast genomics to treatment
Authors: Nadhir Yousfi, Cyril Mousseaux, Abderaouf Hamza, Pierre Laville, Marie Mille, Nicolas Philippe, Marine Dancer, Christophe Bouder, Yosu Luque, Cédric Rafat, Laurent Mesnard
Journal: Blood (2024)
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
Authors: Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa McKiver, Paula Rodríguez-Otero
Journal: Blood (2024)

Abstract Outcomes are poor in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (R/RMM). In the phase 3 KarMMa-3 trial, patients with TCE R/RMM and 2 to 4 prior regimens were randomized 2:1 to idecabtagene vicleucel (ide-cel) or standard regimens (SRs). An interim analysis (IA) demonstrated significantly longer median progression-free survival (PFS; primary end point; 13.3 vs 4.4 months; P &amp;lt; .0001) and higher overall response rate (ORR) with ide-cel vs SRs. At final PFS analysis (median follow-up, 30.9 months), ide-cel further improved median PFS vs SRs (13.8 vs 4.4 months; hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.38-0.63). PFS benefit with ide-cel vs SRs was observed regardless of number of prior lines of therapy, with greatest benefit after 2 prior lines (16.2 vs 4.8 months, respectively). ORR benefit was maintained with ide-cel vs SRs (71% vs 42%; complete response, 44% vs 5%). Patient-centric design allowed crossover from SRs (56%) to ide-cel upon progressive disease, confounding overall survival (OS) interpretation. At IA of OS, median was 41.4 (95% CI, 30.9 to not reached [NR]) vs 37.9 (95% CI, 23.4 to NR) months with ide-cel and SRs, respectively (HR, 1.01; 95% CI, 0.73-1.40); median OS in both arms was longer than historical data (9-22 months). Two prespecified analyses adjusting for crossover showed OS favoring ide-cel. This trial highlighted the importance of individualized bridging therapy to ensure adequate disease control during ide-cel manufacturing. Ide-cel improved patient-reported outcomes vs SRs. No new safety signals were reported. These results demonstrate the continued favorable benefit-risk profile of ide-cel in early-line and TCE R/RMM. This trial was registered at www.ClinicalTrials.gov as #NCT03651128.
IL-22Ra2 Levels Remain Elevated in People with Cystic Fibrosis Despite Modulator Therapy
Authors: Christine M. Bojanowski, Stella E. Lee, Giraldina Trevejo-Nunez, Jennifer M. Bomberger, Robert P. Schleimer, Milene T. Saavedra, Jay K. Kolls
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

"IL-22Ra2 Levels Remain Elevated in People with Cystic Fibrosis Despite Modulator Therapy." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Lipid-Lowering Medication and Outcomes After Anatomical and Functional Imaging in Suspected Coronary Artery Disease
Authors: Teemu Maaniitty, Matias Mäenpää, Esa Harjulahti, Iida Kujala, Iida Stenström, Wail Nammas, Juhani Knuuti, Antti Saraste
Journal: JACC. Cardiovascular imaging (2024)

Anatomical and functional imaging identify different phenotypes of coronary artery disease (CAD) that may have implications for lipid-lowering medication (LLM).
Prevalence of Abnormal Atrial and Ventricular Mechanics and Its Reversibility in Patients With Atrial Fibrillation
Authors: Koki Nakanishi, Masao Daimon, Katsuhito Fujiu, Kentaro Iwama, Kazutoshi Hirose, Yuriko Yoshida, Yasuhiro Mukai, Hikari Seki, Yuko Yamamoto, Megumi Hirokawa, Tomoko Nakao, Tsukasa Oshima, Takumi Matsubara, Yu Shimizu, Gaku Oguri, Toshiya Kojima, Eriko Hasumi, Hiroyuki Morita, Makoto Kurano, Issei Komuro
Journal: JACC. Cardiovascular imaging (2024)
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors
Authors: Rushin Patel, Mark Wadid, Bhargav Makwana, Ashish Kumar, Sumanth Khadke, Ammar Bhatti, Ahan Banker, Zaid Husami, Sherif Labib, David Venesy, Gregg Fonarow, Mikhail Kosiborod, Sadeer Al-Kindi, Deepak L. Bhatt, Sourbha Dani, Anju Nohria, Javed Butler, Sarju Ganatra
Journal: JACC Heart Failure (2024)